SCHEMBL19852460

SCHEMBL19852460

COc1ccccc1OC1CCN(CC2COc3ccccc32)CC1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.46
ADRA2A P08913 1/20 0.45
ADRA2B P18089 1/20 0.45
ADRA2C P18825 1/20 0.45
ADRA1D P25100 1/20 0.44
ADRA1A P35348 1/20 0.44
ADRA1B P35368 1/20 0.44
DRD2 P14416 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
HTR2C P28335 2/20 0.39
SIGMAR1 Q99720 2/20 0.39
HTR1A P08908 2/20 0.39
CHRNA7 P36544 1/20 0.39
CYP19A1 P11511 1/20 0.39
LTA4H P09960 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19852004 0.90 KCNH2 (0.55) KCNH2ADRA2AADRA2BADRA2CADRA1D
SCHEMBL19852469 0.86 PPARG (0.40) KCNH2ADRA2AADRA2BADRA2CADRA1D
SCHEMBL21072473 0.81 HTR7 (0.42) HTR2CSIGMAR1HTR1A
SCHEMBL19852300 0.79 HTR7 (0.47) DRD2MEN1KMT2AHTR2CSIGMAR1
SCHEMBL19852425 0.78 HTR7 (0.42) KCNH2ADRA2AADRA2BADRA2CADRA1D
SCHEMBL19852462 0.77 OPRM1 (0.40) KCNH2ADRA2AADRA2BADRA2CADRA1D
SCHEMBL25619737 0.77 LMNA (0.50) KCNH2DRD2SIGMAR1HTR1A
SCHEMBL19852003 0.73 KCNH2 (0.41) KCNH2MEN1KMT2AHTR1A
SCHEMBL19852005 0.73 HTR1A (0.50) KCNH2ADRA1DADRA1AADRA1BHTR1A
SCHEMBL19852349 0.73 SIGMAR1 (0.52) DRD2HTR2CSIGMAR1HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11186564-B2 Dual NAV1.2/5HT2a inhibitors for treating CNS disorders SUNOVION PHARMACEUTICALS INC. (US) 2021-11-30 US disclosed
US-11186564-B2 Dual NAV1.2/5HT2a inhibitors for treating CNS disorders SUNOVION PHARMACEUTICALS INC. (US) 2021-11-30 US disclosed
US-20190194163-A1 DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS SUNOVION PHARMACEUTICALS INC. (US) 2019-06-27 US disclosed
US-20190194163-A1 DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS SUNOVION PHARMACEUTICALS INC. (US) 2019-06-27 US disclosed
WO-2018026371-A1 DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS SUNOVION PHARMACEUTICALS INC. (US) 2018-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190194163-A1 DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS SCN2A, HTR2A, HTR2C KCNH2 158/4885ADRA2A 92/4885ADRA2B 149/4885
US-11186564-B2 Dual NAV1.2/5HT2a inhibitors for treating CNS disorders SCN2A, HTR2A, HTR2C KCNH2 158/4885ADRA2A 92/4885ADRA2B 149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.